About Us

/About Us
About Us 2018-04-24T15:19:13+00:00

Our Focus

Supportive Care

Medicines that treat or manage secondary conditions arising from, relating to and complicated by underlying serious, chronic and long-term diseases.

Genito-Urinary Medicine

Medicines that treat or manage conditions related to sexual and reproductive health in both women and men.

Customer Care

Healthcare products that manage or treat common conditions that can be self-treated or managed with the assistance of healthcare professionals.

Our Expertise

Kora Healthcare is a fully integrated healthcare company with core competencies across Research, Development & Innovation, Scientific & Medical Affairs, Regulatory Affairs & Pharmacovigilance, Quality, Supply Chain, Marketing & Sales, Finance and Customer Services. All departments are led from our headquarters in Dublin, Ireland with UK sales and marketing operations located in York, UK.

Kora Healthcare is accredited and certified to Good Manufacturing Practice, Good Distribution Practice, ISO 13485 and holds a manufacturing license and wholesale license for product portfolio assets. Kora Healthcare operates under a virtual manufacturing platform in that Kora Healthcare manufactures through an established network of contract manufacturing organisations and contract research organisations for development and commercial manufacturing.

Kora Healthcare operates broadly along two business models:

Our ‘Home Markets’ model supported by our established infrastructure across the UK, Ireland and Germany involves a mix of internally developed portfolio products and in-licensed products.

Our ‘International Markets’ model, by contrast, is focussed on developing long-term licensee’s and distributors with a like-minded therapy focus across global markets, supported by our internal team.

As a business we are resourced and optimally-sized to delivery continued growth for several years from our portfolio of currently marketed products, coupled with multiple opportunities for continued geographical expansion anticipating the delivery on our product development pipeline. Our development pipeline builds on existing therapeutic areas of focus and lifestyle brands of the patients and consumers we serve.

Our current priorities include optimising the international market expansion of ready –to-market, Magnaspartate and increasing the global footprint of brands such as Relactagel and Regelle. Together with our international focus, we continue to ensure launch readiness for our ever-evolving research, development and innovation pipeline.

Contact Kora Healthcare:

Receive updates from Kora Healthcare

 

The Kora Story

alt-text

Our Vision

At Kora Healthcare, we strive to build a sustainable, growth-orientated and profit-driven business through delivery of a robust product portfolio and pipeline. By fostering a culture of innovation and quality, we will continue to anticipate, understand and respond to patient needs quickly and thoroughly.

Leadership Team

The Kora Healthcare Leadership combines commercial and technical experience that spans decades of senior leadership across the pharmaceutical and medical device industry. By fostering a culture of innovation and quality our leadership team is focussed on building sustainable, growth-orientated and value-driven business.

We are seeking to engage with external partners, identify, develop and commercialise healthcare products international and to fully realise the potential and value of our established company infrastructure.

Kora Healthcare Team

Conor O’Daly
Chief Executive Officer

Working with Kora Healthcare since 2010 across commercial functions, Conor O’Daly became a Chief Executive Officer in August 2016. Prior to joining Kora Healthcare, Conor worked with a then sister company to Kora Healthcare, Newport Pharmaceuticals. Conor holds a BA in International Business (Finance) with languages and subsequently completed a number of post-graduate diplomas across commercial disciplines. Conor also is an executive director on the Kora Healthcare Board of Directors.

Kora Healthcare Team

Aidan Ryan
Group Financial Controller

Aidan Ryan is responsible for managing all aspects of the financial function at Kora Healthcare. Aidan joined Kora Healthcare in November 2011 and has been Group Financial Controller since 2016. Aidan became a member of the Institute of Chartered Accountants on 6th July 2010, has completed a diploma in Healthcare Economics and has previous experience working as an auditor in the Financial Services & SME sectors.

Kora Healthcare Team

Mark Blowers
Commercial Director (UK ethical)

Working with Kora Healthcare since 2009 Mark has over 30 years of pharmaceutical and nutrition industry experience. Mark strives to ensure maximum sales growth and long term return on investment for Kora UK and its product portfolio through the development and optimisation of its sales teams, marketing approaches and customer macro influencers.

Kora Healthcare Team

Natasha Bankowski
Regulatory & Pharmacovigilance Manager

Natasha has experience working in the Pharmaceutical and Medical Device Industry for over 10 years. She has worked across multiple areas including Quality Management, Regulatory Affairs, Medical Affairs, Pharmacovigilance and R&D. She has managed the Global Regulatory Affairs, Pharmacovigilance and Medical Affairs Departments and has been successful in building the global footpath with registrations in over 150 countries. Natasha holds a BSc in Medicinal Chemistry from Trinity College, Dublin and completed a further Higher Diploma in Pharmaceutical Production.

Kora Healthcare Team

Matt Connolly
Commercial Director (Rest of World & OTC)

Matt joined Kora Healthcare in November 2016 and operates as Commercial Director for Ireland, Group OTC & International markets driving group sales, marketing and business development. Prior to joining Kora Healthcare Matt was VP of Sales and Marketing for Trulife Medical Devices and consulted with companies on projects across the UK, Iberia and the Middle East. Matt also spent over 12 years with Lifes2good Healthcare building the business and brands internationally with particular focus on EMEA markets.

Kora Healthcare Team

Sinead Healy
Scientific & Medical Affairs Manager

Sinead has responsibility for Development, Manufacturing Support and Medical Affairs at Kora Healthcare. Sinead worked for 10 years at Abbott Diagnostics in technical leadership roles in quality, product technical support and validation. Sinead also worked as a Cell Culture Manager, responsible for the upstream commercial production of recombinant Follicle Stimulating Hormone (FSH). Sinead graduated with a degree in Industrial Biochemistry from the University of Limerick and earned a Ph.D. in Cell Biology /Immunology from Trinity College Dublin, and went on to work as a post-doctoral researcher in the areas of colon cancer and asthma.

Kora Healthcare Team

Michael Mulvey
Quality Manager

Michael is responsible for the Quality Management System at Kora Healthcare.  He graduated from Trinity College Dublin with a Masters in Microbiology.  He has worked in Healthcare manufacturing for 30 years and has completed significant training programs in Quality and a Higher Diploma in Pharmaceutical Manufacturing Technology.

Board of Directors

The Kora Healthcare Board of Directors provides the leadership, guidance and governance necessary to execute our mission, vision and strategy now and into the future.

  • Darren Cunningham | Chairman

  • James O’Daly | Non-Executive Director

  • Joan O’Daly | Company Secretary

  • Shauna Lord | Non-Executive Director

  • Clodagh Kelly | Non-Executive Director

  • Conor O’Daly | Executive Director

Immdal Group

Immcell

Kora Healthcare is a 100% privately owned healthcare company and a subsidiary of Immdal Ltd Group.

The Immdal Ltd Group consists of Kora Healthcare and Immcell Ltd, a sister company to Kora Healthcare, and is wholly owned by the O’Daly family. Immdal Ltd seeks to develop additional commercial subsidiaries with growth potential capable of delivering regular income and profits to the group including but not limited to; biotechnology, finished pharmaceuticals, novel technology platform, active ingredients across both food and pharmaceuticals, animal health, bio-marine products, renewable and sustainable energies and commercial property.

Visit the Immcell website